Dec 9 (Reuters) - Sirtex Medical Ltd (SRX) :
- On a full year basis, worldwide dose sales growth is anticipated to be in order of 5-11% compared to growth of 16.4% achieved in fy16
- Constant currency EBITDA for full year is anticipated to be in range $65-74 million
News: SRX Sirtex Medical provides FY ending June 2017 guidance
Add to My Watchlist
What is My Watchlist?